These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1146 related articles for article (PubMed ID: 25539810)

  • 1. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
    Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV; Dhodapkar KM
    J Immunol; 2015 Feb; 194(3):950-9. PubMed ID: 25539810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 5. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations.
    Baksh K; Weber J
    Semin Oncol; 2015 Jun; 42(3):363-77. PubMed ID: 25965355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.
    Okoye IS; Xu L; Walker J; Elahi S
    Cancer Immunol Immunother; 2020 Aug; 69(8):1423-1436. PubMed ID: 32246174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
    Shi LZ; Fu T; Guan B; Chen J; Blando JM; Allison JP; Xiong L; Subudhi SK; Gao J; Sharma P
    Nat Commun; 2016 Aug; 7():12335. PubMed ID: 27498556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
    Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
    Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Shin DS; Ribas A
    Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
    Salama AK; Moschos SJ
    Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
    Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
    Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.